This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Pacira Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on innovative solutions for pain management and surgical care. Founded in 2006, Pacira has made significant strides in the industry, particularly with its flagship product, EXPAREL, a long-acting local anaesthetic that enhances postoperative pain control while reducing the need for opioids. With a commitment to advancing patient care, Pacira operates primarily in North America and has expanded its reach into various surgical specialties. The company is recognised for its unique approach to pain management, positioning itself as a pioneer in the development of non-opioid therapies. Notable achievements include a strong market presence and partnerships that further its mission to improve surgical outcomes and patient recovery.
DitchCarbon Score
How does Pacira Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pacira Pharmaceuticals, Inc.'s score of 25 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pacira Pharmaceuticals, Inc.'s reported carbon emissions
Pacira Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures in kg CO2e. The company is a current subsidiary of Pacira BioSciences, Inc., which may influence its climate commitments and reporting practices. Despite the lack of direct emissions data, Pacira Pharmaceuticals has not publicly outlined any specific reduction targets or initiatives related to carbon emissions. There are no commitments to the Science Based Targets initiative (SBTi) or other climate pledges noted in the available information. As a subsidiary, Pacira Pharmaceuticals may inherit climate-related strategies and data from its parent company, Pacira BioSciences, Inc., but specific details on emissions or reduction initiatives from this source are not provided. The absence of concrete data highlights a potential area for improvement in transparency and commitment to climate action within the pharmaceutical industry.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pacira Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
